T6654
Ticlopidine hydrochloride
analytical standard, for drug analysis
Synonym(s):
5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C14H14ClNS · HCl
CAS Number:
Molecular Weight:
300.25
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
258-837-4
MDL number:
Quality Level
assay
≥99%
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
SMILES string
Cl.Clc1ccccc1CN2CCc3sccc3C2
InChI
1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H
InChI key
MTKNGOHFNXIVOS-UHFFFAOYSA-N
Gene Information
human ... P2RY12(64805)
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Ticlopidine hydrochloride has been used as an analytical standard to investigate the developmental toxicity and teratogenic potential of ticlopidine in Xenopus laevis embryos and human endothelial cells using a frog embryo teratogenesis assay-Xenopus (FETAX) and blood and lymph vessel formation assay.
Still not finding the right product?
Explore all of our products under Ticlopidine hydrochloride
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Characterization of ticlopidine-induced developmental and teratogenic defects in Xenopus embryos and human endothelial cells.
Park SM, et al.
Chemico-Biological Interactions, 240, 172-178 (2015)
Jan H Cornel et al.
American heart journal, 168(1), 76-87 (2014-06-24)
To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without
Stephen D Wiviott et al.
Lancet (London, England), 382(9892), 605-613 (2013-08-21)
Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only.